Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update
Aclaris Therapeutics reported Q2 2026 revenue of $1.6 million with a net loss of $21.5 million, while subsequent ATM sales of 7.3 million shares raised $40.2 million to extend its cash runway into the end of 2028. The company announced positive full top-line results from the Phase 1a trial of ATI-052, demonstrating a favorable safety profile and pharmacokinetics that support potential quarterly dosing.
Key figures
- Revenue
- 1629000
- Net loss
- $21.5 million
- Cash runway
- end of 2028
- Rd expenses
- $18.1 million
- Atm proceeds
- $40.2 million
- Cash position
- $170.6 million
- Atm shares sold
- 7.3 million
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.